Ardena has officially become a member of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs. This membership reflects Ardena’s commitment to collaborating with like-minded companies and contributing to shaping policies that support the advancement of the life sciences industry in Europe.
According to our CEO Harry Christiaens, “joining EUCOPE presents a unique opportunity for Ardena to expand our network, stay informed on the latest developments and trends in pharmaceutical innovation policies in Europe, and bring our expertise to the table after successfully supporting small and mid-sized biotechs in bringing numerous drugs to clinical trials. Our extensive experience navigating complex regulatory pathways and our capabilities to develop treatments for rare diseases align with EUCOPE’s mission.”
EUCOPE represents over 100 innovative biotech and SME pharma companies, advocating for a dynamic, patient-centric, and sustainable healthcare ecosystem. Ardena’s expertise in drug development and manufacturing will complement EUCOPE’s efforts to promote a competitive and diversified European biopharmaceutical sector. The company’s state-of-the-art facilities and experienced team of scientists offer a range of services to support drug development, from drug substance through to drug product, bioanalysis and CMC regulatory support.
Through its membership in EUCOPE, Ardena will have the opportunity to contribute to policy development and engage in dialogue with key stakeholders. This collaboration will also provide Ardena with the latest information and insights on regulatory, scientific, and policy issues affecting the life sciences industry in Europe.